The FDA this afternoon issued an emergency use authorization for the investigational antiviral drug remdesivir to treat severely ill COVID-19 patients.
The authorization for the drug, made by Gilead Sciences’ (NSDQ:GILD), will allow both adults and children to be treated with the remdesivir, the first drug believed to have any effect on the virus that has sickened millions and caused hundreds of thousands of deaths. Gilead said today that it aims to produce at least 500,000 treatment courses by October, 1 million treatment courses by December 2020 and millions more in 2021, if required.
Get the full story on our sister site, MassDevice.
Filed Under: clinical trials, Drug Discovery and Development, Infectious Disease
